Press Releases April 28, 2026 04:15 PM

eXp World Holdings to Announce First Quarter 2026 Results on May 11, 2026

eXp World Holdings schedules Q1 2026 earnings release and investor Q&A session

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
EXPI

eXp World Holdings, a Nasdaq-listed company and parent of eXp Realty and other businesses, announced it will report first quarter 2026 financial results on May 11, 2026. The company will host a virtual fireside chat and investor Q&A on the same day to discuss the results and business updates.

eXp World Holdings to Announce First Quarter 2026 Results on May 11, 2026
EXPI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Q1 2026 earnings release scheduled for May 11, 2026, with a virtual investor Q&A to follow.
  • eXp World Holdings operates a cloud-based real estate brokerage platform with global reach spanning multiple continents.
  • The company emphasizes agent-centric business model offering competitive commissions, revenue share, and equity ownership, underscoring innovation in real estate services.

BELLINGHAM, Wash., April 28, 2026 (GLOBE NEWSWIRE) -- eXp World Holdings, Inc. (Nasdaq: EXPI), the holding company for eXp Realty®, FrameVR.io and SUCCESS® Enterprises, today announced it expects to report its first quarter 2026 financial results on Monday, May 11, 2026.

The Company will hold a virtual fireside chat and investor Q&A on Wednesday, May 11, 2026 at 5:30 a.m. PT / 8:30 a.m. ET hosted by:

  • Glenn Sanford, Founder, Chairman and CEO, eXp World Holdings
  • Leo Pareja, CEO, eXp Realty
  • Jesse Hill, Chief Financial Officer, eXp World Holdings

The investor Q&A is open to investors, current stockholders and anyone interested in learning more about eXp World Holdings and its companies. Submit questions in advance to [email protected].

First Quarter 2026 Investor Q&A
Date: Monday, May 11, 2026
Time: 5:30 a.m. PT / 8:30 a.m. ET
Location: exp.world. Join at https://exp.world/earnings
Livestream: expworldholdings.com/events

About eXp World Holdings, Inc.

eXp World Holdings, Inc. (Nasdaq: EXPI) is the parent company of eXp Realty®, “the most agent-centric™ real estate brokerage on the planet,” FrameVR.io and SUCCESS® Enterprises. Through a cloud-based platform and agent-centric model, eXp Realty empowers real estate professionals with industry-leading commission structures, revenue share, equity ownership, and access to a global community. With operations spanning the Americas, Europe, the Middle East, Asia Pacific, and South Africa, eXp continues to redefine how agents connect, grow, and succeed in real estate. As a publicly traded company, eXp World Holdings prioritizes transparency, innovation, and long-term value for agents, staff, and shareholders.

Media Relations Contact:

eXp World Holdings, Inc.

[email protected]

Investor Relations Contact:

Denise Garcia

[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/abdc5523-d985-4c87-934d-323cf10c3716


Risks

  • Market performance may be impacted by the upcoming Q1 financial results which could differ from investor expectations.
  • Global real estate markets and economic conditions across the Americas, Europe, Middle East, and Asia Pacific may create variability in operational results.
  • Competition within the real estate brokerage and virtual platform sectors presents ongoing challenges to growth and profitability.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026